½ÃÀ庸°í¼­
»óǰÄÚµå
1308654

¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀå ¿¹Ãø(-2030³â) - Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº° ¼¼°è ºÐ¼®

Facial Injectables Market Forecasts to 2030 - Global Analysis By Product Type, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀº 2023³â 59¾ï 4,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È CAGR 11.6%·Î ¼ºÀåÇØ 2030³â¿¡´Â 128¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇǺΠÇÊ·¯´Â ¾ó±¼ ÁÖ»çÁ¦¶ó°íµµ ºÒ¸®¸ç ¾ó±¼À» Àþ¾îÁö°Ô ÇÏ´Â È­ÀåǰÀÔ´Ï´Ù. ¹ÌÀû ¾Æ¸§´Ù¿òÀ» Çâ»ó½Ã۱â À§ÇØ ÀÌ·¯ÇÑ ¾È¸é ÁÖ»ç Á¦Ç°Àº ÀϹÝÀûÀ¸·Î ÁÖ¸§ ¹× ±âŸ ³ëÈ­ÀÇ Ãʱâ ¡Èĸ¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í Àΰø ¼ö»êÈ­Ä®½· ÇÊ·¯¿Í °°Àº ¿ì¼öÇÑ ¾È¸é ÁÖ»çÁ¦ °³¹ß¿¡µµ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹¼ºÇü¿Ü°úÇÐȸ(ASPS)¿¡ µû¸£¸é 2019³â ¹Ì±¹ ³» ¼ºÇü¼ö¼úÀÇ 25.0%°¡ º´¿ø¿¡¼­ ÀÌ·ïÁø °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

ÃËÁø¿äÀÎ:

ÃÖ¼Òħ½ÀÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ¼¼°è ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀº ÃÖ¼ÒÇÑÀÇ È¸º¹ ½Ã°£, ÅëÁõ °¨¼Ò, ¼ö¼ú°ú °ü·ÃµÈ À§Çè °¨¼Ò¸¦ ¿øÇϱ⠶§¹®¿¡ ºñħ½ÀÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ¾øÀÌ ¿Ü¸ð¸¦ °¡²Ù°í ½Í¾îÇÏ´Â »ç¶÷µé¿¡°Ô ¾È¸é ÁÖ»çÁ¦´Â Æí¸®ÇÏ°í ºñħ½ÀÀûÀÎ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¼Ò¼È ¹Ìµð¾î¿Í ÃÖ°íÀÇ ¸ð½ÀÀ» º¸¿©ÁÖ°íÀÚ ÇÏ´Â »ç¶÷µéÀÇ ¿å±¸°¡ ³ô¾ÆÁö¸é¼­ ¹ßÀüÇÑ ¼¿Ä« ¹®È­µµ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¾ïÁ¦¿äÀÎ:

¸Å¿ì °í°¡

¼¼°è ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÈ÷ ¸¹Àº »ç¶÷µé¿¡°Ô Ä¡·á ºñ¿ëÀÌ ºÎ´ã½º·¯¿î °³¹ßµµ»ó±¹¿¡¼­´Â ³ôÀº °¡°ÝÀÇ ¾È¸é ÁÖ»çÁ¦°¡ ȯÀÚ À¯ÀÔ¿¡ Å« À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ³ôÀº °¡°ÝÀº ȯÀÚµéÀÌ À¯Áö Áֻ縦 ¹Þ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µé ¼ö ÀÖÀ¸¸ç, ±× °á°ú ±â¾÷ÀÇ Àüü ½ÃÀå ¼öÀÍÀÌ °¨¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ÀϺΠ»ç¾÷ÀÚµéÀº Á¤¾×Á¦¿Í °°Àº ´Ù¸¥ °¡°Ý ü°è¸¦ °í·ÁÇϰí ÀÖ½À´Ï´Ù.

±âȸ:

º¹ÇÕÄ¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡

¼¼°è ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÊ·¯¿Í ½Å°æ Á¶ÀýÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¾È¸é ÁÖ»çÁ¦¸¦ È¥ÇÕÇÏ´Â º´¿ë ¿ä¹ýÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¿©·¯ Ä¡·á¹ýÀ» ÅëÇÕÇÑ Á¾ÇÕÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ±â¾÷Àº ÀÌ·¯ÇÑ Ãß¼¼¿¡¼­ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ´Â À¯¸®ÇÑ À§Ä¡¿¡ ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÇÑ ¿¹·Î, ÇöÀç ÀϺΠ±â¾÷µéÀº ÁÖ»çÁ¦¿Í ´Ù¸¥ ÃÖ¼Òħ½ÀÀû ±â¼úÀ» °áÇÕÇÏ¿© ¿Ïº®ÇÑ ¾ó±¼ ȸÃá ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â '¸®Äûµå ÆäÀ̽º ¸®ÇÁÆ®(Liquid Face Lift)' Ä¡·á¹ýÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

À§Çù:

°ø±Þ¸ÁÀÇ È¥¶õ

¼¼°è ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¿ø·á ¹× Á¦Á¶ ÀåºñÀÇ ºÎÁ·À¸·Î ÀÎÇØ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀåÀÇ È¥¶õÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°Àº Á¦Ç° °³¹ß ¹× Á¦Á¶ Áö¿¬, °ø±Þ·® °¨¼Ò, ¼ÒºñÀÚ °¡°Ý »ó½ÂÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ±â¾÷µéÀº ÀÌ·¯ÇÑ À§Çù¿¡ ´ëÀÀÇϱâ À§ÇØ °ø±Þ¸ÁÀ» ´Ùº¯È­Çϰí, Àç°í °ü¸® ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí, °ø±Þ¾÷ü¿Í ±ä¹ÐÇÑ °ü°è¸¦ À¯ÁöÇÏ¿© ¾ÈÁ¤ÀûÀÎ ¿øÀÚÀç °ø±ÞÀ» º¸ÀåÇØ¾ß ÇÕ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19 ÆÒµ¥¹ÍÀº ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á, ±ÝÀ¶ ºÒ¾È, °ø±Þ¸Á È¥¶õ, ±ÔÁ¦ ´ç±¹ÀÇ °­È­µÈ °¨½Ã·Î ÀÎÇØ ¾È¸é ÁÖ»çÁ¦ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÄ ¼ö¿ä °¨¼Ò¸¦ °¡Á®¿Ô½À´Ï´Ù. ÀÌ¿¡ ÀûÀÀÇϱâ À§ÇØ ±â¾÷µéÀº »õ·Î¿î ±â¼ú, ¾ÈÀü ÀýÂ÷ ¹× Á¦Ç° °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀÌ Àü¿°º´ÀÇ ¾î·Á¿òÀ» ±Øº¹ÇÔ¿¡ µû¶ó ½ÃÀåÀº ¿ªµ¿ÀûÀ̰í Çõ½ÅÀûÀÎ »óŸ¦ À¯ÁöÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. Àü ¼¼°è°¡ Àü¿°º´ÀÇ µµÀü¿¡ ´ëóÇϱâ À§ÇØ °í±ººÐÅõÇÏ´Â µ¿¾È ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀº ¿ªµ¿ÀûÀ̰í Çõ½ÅÀûÀÏ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

ÇǺΠÇÊ·¯ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ±Ô¸ð¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»ó:

ÇǺΠÇÊ·¯ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÇǺΠÇÊ·¯´Â ¿Ü°úÀû ½Ã¼ú°ú ºñ±³ÇÒ ¶§ È¿À²¼º, °æÁ¦¼º ¹× »ó´ëÀûÀ¸·Î ³·Àº ÇÕº´Áõ À§ÇèÀ¸·Î ÀÎÇØ ÀαⰡ ÀÖ½À´Ï´Ù. À̵éÀº º¼·ýÀ» ȸº¹Çϰí ÁÖ¸§À» ºÎµå·´°Ô ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ È®»êÀº ´Ù¾çÇÑ Á¦Çü°ú ÁÖÀÔ ¹æ¹ýÀ» °¡Áø ´Ù¾çÇÑ ÇǺΠÇÊ·¯ Á¦Ç°À» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÈ µ¥ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. Àα¸ °í·ÉÈ­, ºñ¼ö¼úÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ Àνİú ¼ö¿ë¼º Áõ°¡, Áö¼ÓÀûÀÎ Á¦Ç° Çõ½ÅÀº ¸ðµÎ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀÔ´Ï´Ù. ½ÃÀå °³Ã´À» ÃßÁøÇÏ´Â ±â¾÷µéÀº ÁøÇÇ ÇÊ·¯¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ³ªÀº °á°ú, ´õ ¿À·¡ Áö¼ÓµÇ´Â È¿°ú, ´õ ÀûÀº ºÎÀÛ¿ëÀ» Á¦°øÇÏ´Â °³¼±µÈ ½ÅÁ¦Ç°À» °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»ó:

¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)´Â ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)¿¡¼­ ¿Ü¸ð¸¦ °³¼±ÇϰíÀÚ Çϴ ȯÀÚµéÀÌ ¾È¸é ÁÖ»çÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¿Ü°úÀû ¹× ºñ¼ö¼úÀû ½Ã¼ú Áß¿¡¼­ ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀ¸·Î´Â ÃÖ¼Òħ½ÀÀû ¹Ì¿ë ¼ºÇü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾È¸é ÁÖ»çÁ¦ÀÇ ÀåÁ¡¿¡ ´ëÇÑ Áö½Ä Áõ°¡, ASCÀÇ ¼ö¿ë¼º È®´ë µîÀÌ ÀÖ½À´Ï´Ù. ¸¹Àº ASC´Â ȯÀÚ¿¡°Ô ¾ÈÀüÇϰí È¿°úÀûÀÎ ¹Ì¿ë ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ »õ·Î¿î ±â¼ú, Àåºñ ¹× Á÷¿ø ±³À°¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª:

ºÏ¹Ì Áö¿ª ½ÃÀåÀº ºñħ½ÀÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ¾È¸é ÁÖ»çÁ¦ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¹Ì±¹Àº ºÏ¹Ì¿¡¼­ °¡Àå Å« ¾È¸é ÁÖ»çÁ¦ ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀåÀº ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁø µ¥´Ù ´Ù¾çÇÑ ¾ó±¼¿ë ÁÖ»çÁ¦ Á¦Ç°ÀÌ Ãâ½ÃµÇ¸é¼­ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹ÌÀÇ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È ÃÖ¼Òħ½ÀÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ±â¼úÀÌ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñ¼ö¼úÀû ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ »ç¶÷µéÀÇ Àνİú ¼ö¿ë¼º Áõ°¡ µîÀÌ ÀÌ Áö¿ªÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÃÖ½ÅÀÇ Çõ½ÅÀûÀÎ ¾È¸é ÁÖ»ç Á¦Ç°ÀÇ °¡¿ë¼º°ú ÀÌ·¯ÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ·á ½Ã¼³ ¹× ÀÇ·á Àü¹®°¡ÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ű¹, Çѱ¹, Àεµ µîÀÇ ±¹°¡¿¡¼­ ÀÇ·á °ü±¤ÀÌ È®´ëµÊ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È¸é ÁÖ»ç±â ½ÃÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ¹ßÀü:

2022³â 8¿ù, Allergan Healthcare IndiaÀÇ Allergan Aesthetics »ç¾÷ºÎ´Â ¾ó±¼ÀÇ º¼·ýÀ» ȸº¹ÇÏ°í »ý¼ºÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÏ´Â ÁÖ»çÇü ÀÓÇöõÆ®ÀÎ Juvederm VOLUX¸¦ Ãâ½ÃÇß½À´Ï´Ù.

2022³â 3¿ù, °¥´õ¸¶´Â AMWC 2022¿¡¼­ ÇǺΠÇÊ·¯, Äݶó°Õ ¹ÙÀÌ¿À ÀÚ±ØÁ¦ ¹× ¾×ü ½Å°æ Á¶ÀýÁ¦ Æ÷Æ®Æú¸®¿À¿¡ ´ëÇÑ »õ·Î¿î ÀÓ»ó µ¥ÀÌÅÍ¿Í ³ôÀº ȯÀÚ ¸¸Á·µµ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. °¥´õ¸¶´Â Aesthetic &Anti-Aging Medicine World Congress 2022¿¡¼­ È÷¾Ë·ç·Ð»ê ÇǺΠÇÊ·¯ ½Ã¸®Áî, ÃÖÃÊÀÇ ¾×ü ½Å°æ Á¶ÀýÁ¦, ¿À¸®Áö³Î Äݶó°Õ »ýü ÀÚ±ØÁ¦ µî ÀÚ»çÀÇ Æ÷Æ®Æú¸®¿À¿¡ ´ëÇÑ ´Ù¾çÇÑ »õ·Î¿î °úÇÐÀû µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù.

2022³â 2¿ù, ¾Ï´ÒÀº 4°³ÀÇ ½ÅÁ¦Ç°À¸·Î ÁÖ»çÁ¦ Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇß½À´Ï´Ù. µ¦»ç¸ÞŸ¼Õ Àλ곪Ʈ·ý Àλ꿰 ÁÖ»çÁ¦ USP 10mg/mL, ¾ÆÀÚ½ÃÆ¼µò 100mg, Ä«º¸ÇÁ·Î½ºÆ®·Î½ºÆ®·Î¸ÞŸ¹Î ÁÖ»çÁ¦ USP 250mcg/mL, ¾ÆÆ®·ÎÇÉ È²»ê¿° ÁÖ»çÁ¦ USP 0.5mg/5mL°¡ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ °£¼ÒÈ­µÈ ½Å¾à ½ÂÀÎ ½Åû¼­¸¦ Á¦ÃâÇß½À´Ï´Ù. µ¦»ç¸ÞŸ¼Õ°ú ¾ÆÀÚ½ÃÆ¼µòÀº ÇöÀç FDAÀÇ ÀǾàǰ ºÎÁ· ¸ñ·Ï¿¡ µîÀçµÇ¾î ÀÖÀ¸¸ç, ¾ÆÆ®·ÎÇÉÀº FDA·ÎºÎÅÍ °æÀï Á¦³×¸¯ ÀǾàǰ(Competitive Generic Therapy) ÀÎÁõÀ» ¹Þ¾Ò½À´Ï´Ù.

º¸°í¼­ ³»¿ë

  • Áö¿ª ¹× ±¹°¡º° ½ÃÀå Á¡À¯À² Æò°¡
  • ½Å±Ô ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Àü·«Àû Á¦¾ð
  • 2021³â, 2022³â, 2023³â, 2026³â, 2030³â ½ÃÀå µ¥ÀÌÅ͸¦ Æ÷ÇÔ
  • ½ÃÀå µ¿Çâ(½ÃÀå ÃËÁø¿äÀÎ, Á¦¾à¿äÀÎ, ±âȸ, À§Çù, °úÁ¦, ÅõÀÚ±âȸ, ±Ç°í»çÇ×)
  • ½ÃÀå ÃßÁ¤¿¡ ±â¹ÝÇÑ ÁÖ¿ä »ç¾÷ ºÎ¹®¿¡ ´ëÇÑ Àü·«Àû Á¦¾ð
  • ÁÖ¿ä ÀϹÝÀû Æ®·»µå¸¦ ¸ÅÇÎÇÑ °æÀï »óȲ
  • »ó¼¼ÇÑ Àü·«, À繫 ¹× ÃÖ±Ù µ¿ÇâÀ» Æ÷ÇÔÇÑ ±â¾÷ °³¿ä
  • Ãֽбâ¼ú ¹ßÀüÀ» ¸ÅÇÎÇÏ´Â °ø±Þ¸Á µ¿Çâ

¹«·á ¸ÂÃãÇü ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´¿¡°Ô´Â ´ÙÀ½ Áß ÇϳªÀÇ ¹«·á ¸ÂÃãÈ­ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù:

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç ¼Ò½º

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¸µÅ¬ ¸±·º¼­
    • AÇü º¸Åø¸®´®Åå½Å(º¸Å彺)
  • ÇÇºÎ ÃæÀüÁ¦
    • Äݶó°Õ
    • È÷¾Ë·ç·Ð»ê
    • Ä®½· ÇÏÀ̵å·Ï½Ç¶óÆÄŸÀÌÆ®
    • Æú¸®Á¥»ê
    • Æú¸®¸ÞÆ¿¸ÞŸũ¸±·¹ÀÌÆ® ¸¶ÀÌÅ©·Î½ºÇǾî(PMMA)
    • Áö¹æ ÁÖÀÔ
  • Æú¸®¸Ó ÇÊ·¯
  • ±âŸ Á¦Ç° À¯Çü

Á¦6Àå ¼¼°èÀÇ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀå : ¿ëµµº°

  • ÁÖ¸§ °æ°¨
  • ÆäÀ̽º ¸®ÇÁÆ®
  • ¹ÌÇÐ
  • Ä¡·áÇÐ
  • ¿©µå¸§ ÈäÅÍ Ä¡·á
  • Áö¹æ À§ÃàÁõ Ä¡·á
  • ÆäÀ̽º¶óÀÎ º¸Á¤
  • ÀÔ¼ú È®´ë¼ú
  • ±âŸ ¿ëµµ

Á¦7Àå ¼¼°èÀÇ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ÇǺΰú Ŭ¸®´Ð
  • ÄÚ½º¸Þƽ ¼¾ÅÍ
  • ÇǺΰú ¿¬±¸ ±â°ü
  • ¹Ì¿ë Ŭ¸®´Ð
  • ¸ÞµðÄà ½ºÆÄ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ¼¼°èÀÇ ¾ó±¼¿ë ÁÖ»çÁ¦ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦10Àå ±â¾÷ °³¿ä

  • Allergan, Plc.
  • Alma Laser
  • Anika Therapeutics, Inc.
  • Antares Pharma
  • Bausch Health Companies In
  • BIOPLUS CO., LTD.
  • Bioxis Pharmaceuticals
  • Bloomage BioTechnology Corporation Limited
  • ColBar LifeScience Ltd.
  • Dickinson and Company
  • Galderma Pharma S.A.
  • Ipsen Pharma
  • Medytox, Inc.
  • Merz Pharma
  • Prollenium Medical Technologies Inc.
  • Revance Therapeutics, Inc.
  • Sinclair Pharma Plc
  • Solta Medical
  • Suneva Medical, Inc.
  • Syneron Candela
ksm 23.08.09

According to Stratistics MRC, the Global Facial Injectables Market is accounted for $5.94 billion in 2023 and is expected to reach $12.80 billion by 2030 growing at a CAGR of 11.6% during the forecast period. Dermal fillers, also referred to as facial injectable products, are cosmetics that rejuvenate the face. In order to improve aesthetic beauty, these facial injectable products are typically used to treat wrinkles and other early signs of aging. It is also aided in the number of elderly people and the development of superior facial injectables like artificial calcium hydroxylapatite fillers.

According to the American Society of Plastic Surgeons (ASPS), in 2019, an estimated 25.0% of cosmetic procedures were performed in hospitals in the United States.

Market Dynamics:

Driver:

Increasing demand for minimally invasive cosmetic procedures

The global Facial Injectables market expected to drive growth during the forecast period, due to the desire for minimal recovery time, less pain, and fewer risks associated with surgery, the demand for non-invasive cosmetic procedures is increasing quickly. People who want to enhance their appearance without having surgery have a convenient, non-invasive option with facial injectables. Social media and the selfie culture that has developed as a result of people's increasing desire to present their best selves to the world have also contributed to this trend.

Restraint:

Very expensive

The global Facial Injectables market expected to hinder growth during the forecast period. Particularly in developing nations, where the cost of treatment can be prohibitive for many people, the high cost of facial injectables can be a major barrier to patient uptake. Additionally, the high price of these treatments may deter patients from getting maintenance injections, resulting in lower overall market revenue for businesses. In an effort to resolve this problem, some businesses are looking into different pricing structures, like subscription-based plans, which might make facial injectables more affordable for a wider range of patients.

Opportunity:

Rising interest in combination therapies

The global Facial Injectables market expected to drive growth during the forecast period. Combination therapies, which mix various facial injectables, including fillers and neuromodulators, are gaining popularity. Businesses that can provide comprehensive treatment options that incorporate multiple therapies will probably be well-positioned to benefit from this trend. As an illustration, some businesses now provide "liquid facelift" treatments that combine injectables with other minimally invasive techniques to offer a complete facial rejuvenation solution.

Threat:

Disruptions in the supply chain

The global Facial Injectables market expected to hamper growth during the forecast period. A disruption in the facial injectables market could result from a lack of raw materials or manufacturing equipment, for example. These setbacks may result in slower product development and manufacturing, a smaller supply, and higher consumer prices. Companies in the market need to diversify their supply chains, make investments in inventory management systems, and keep strong ties with suppliers to guarantee a steady supply of raw materials to combat this threat.

COVID-19 Impact:

Due to safety concerns, financial uncertainty, disruption of supply chains, and increased regulatory scrutiny, the COVID-19 pandemic has had an impact on the facial injectables market, resulting in decreased demand. To adapt, businesses have made investments in new technologies, safety procedures, and product development. As businesses navigate the challenges of the pandemic, the market is likely to remain dynamic and innovative. The facial injectables market is likely to stay dynamic and innovative as the world struggles to deal with the pandemic's challenges because businesses are working hard to meet patients' changing needs in an environment that is changing quickly.

The dermal fillers segment is expected to be the largest during the forecast period:

The dermal fillers segment is expected to be the largest share during the forecast period Dermal fillers are popular for their efficiency, affordability, and comparably low risk of complications when compared to surgical procedures. They are used to restore volume and smooth out wrinkles. The proliferation of this market has been aided by the accessibility of a wide variety of dermal filler products with various formulations and injection methods. The aging population, rising awareness and acceptance of non-surgical cosmetic procedures, and ongoing product innovation will all contribute to this growth. Companies in the market are likely to invest in R&D to develop new and improved products that offer better results, longer-lasting effects, and fewer side effects as the demand for dermal fillers rises.

The ambulatory surgery centers segment is expected to have the highest CAGR during the forecast period:

The ambulatory surgery centers segment is anticipated to witness the fastest CAGR growth during the forecast period Patients looking to enhance their appearance can choose from a variety of surgical and non-surgical procedures at ambulatory surgery centers (ASCs), including facial injectables. Some of the factors influencing the growth of this market include the rising demand for minimally invasive cosmetic procedures, the growing knowledge of the advantages of facial injectables, and the increasing acceptance of ASCs. In order to offer their patients safe and effective cosmetic services, many ASCs have also made investments in new technologies, equipment, and staff training.

Region with largest share:

The North America region market is estimated to witness a largest share of the global Facial Injectables market during the forecast period, due to the high demand for non-invasive aesthetic procedures, the United States is North America's largest market for facial injectables. The market in this region has expanded as a result of rising awareness and acceptance of cosmetic procedures as well as the availability of a wide variety of facial injectable products. The market for facial injectables in North America is anticipated to expand over the ensuing years, helped along by the rising acceptance of minimally invasive cosmetic procedures and ongoing developments in technology.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The demand for non-surgical cosmetic procedures is rising, there is more disposable income available, and people are becoming more aware of and accepting of aesthetic procedures, all of which contribute to this region's growth. The availability of cutting-edge and novel facial injectable products, as well as the rising number of healthcare facilities and medical professionals providing these services, are anticipated to support growth in this area. Additionally, the market for facial injectables in Asia Pacific is anticipated to expand as a result of the expanding trend of medical tourism in nations like Thailand, South Korea, and India.

Key players in the market

Some of the key players in Facial Injectables market include Allergan, Plc., Alma Laser , Anika Therapeutics, Inc., Antares Pharma , Bausch Health Companies In, BIOPLUS CO., LTD., Bioxis Pharmaceuticals, Bloomage BioTechnology Corporation Limited , ColBar LifeScience Ltd., Dickinson and Company, Galderma Pharma S.A., Ipsen Pharma, Medytox, Inc., Merz Pharma, Prollenium Medical Technologies Inc., Revance Therapeutics, Inc., Sinclair Pharma Plc, Solta Medical, Suneva Medical, Inc. and Syneron Candela.

Key Developments:

In August 2022, Allergan Healthcare India launched Juvederm VOLUX, an injectable implant intended to restore and create the volume of the face, under its Business Unit of Allergan Aesthetics.

In March 2022, Galderma presented its new clinical data and high patient satisfaction across its portfolio of dermal fillers, collagen bio stimulators, and liquid neuromodulators at AMWC 2022. Galderma presented a range of new scientific data on its portfolio on its hyaluronic acid dermal filler range, its first liquid neuromodulator, and its original collagen biostimulator at the Aesthetic & Anti-Aging Medicine World Congress 2022.

In February 2022, Amneal expanded its injectables portfolio with 4 new products. Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received Abbreviated New Drug Application approval from the US Food and Drug Administration. Dexamethasone and azacitidine are both currently on the FDA drug shortage list, and Atroprine was granted Competitive Generic Therapy status by the FDA.

Product Types Covered:

  • Wrinkle Relaxers
  • Dermal Fillers
  • Polymer Fillers
  • Other Product Types

Applications Covered:

  • Wrinkle Reduction
  • Facelift
  • Aesthetics
  • Therapeutics
  • Acne Scar Treatment
  • Lipoatrophy Treatment
  • Facial Line Correction
  • Lip Augmentation
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgery Centers
  • Dermatology Clinics
  • Cosmetic Centers
  • Dermatology Research Institutes
  • Beauty Clinics
  • Medical Spas
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Facial Injectables Market, By Product Type

  • 5.1 Introduction
  • 5.2 Wrinkle Relaxers
    • 5.2.1 Botulinum Toxin Type A
  • 5.3 Dermal Fillers
    • 5.3.1 Collagen
    • 5.3.2 Hyaluronic Acid
    • 5.3.3 Calcium Hydroxylapatite
    • 5.3.4 Polylactic Acid
    • 5.3.5 Polymethyl-methacrylate Microspheres (PMMA)
    • 5.3.6 Fat Injection
  • 5.4 Polymer Fillers
  • 5.5 Other Product Types

6 Global Facial Injectables Market, By Application

  • 6.1 Introduction
  • 6.2 Wrinkle Reduction
  • 6.3 Facelift
  • 6.4 Aesthetics
  • 6.5 Therapeutics
  • 6.6 Acne Scar Treatment
  • 6.7 Lipoatrophy Treatment
  • 6.8 Facial Line Correction
  • 6.9 Lip Augmentation
  • 6.10 Other Applications

7 Global Facial Injectables Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Ambulatory Surgery Centers
  • 7.4 Dermatology Clinics
  • 7.5 Cosmetic Centers
  • 7.6 Dermatology Research Institutes
  • 7.7 Beauty Clinics
  • 7.8 Medical Spas
  • 7.9 Other End Users

8 Global Facial Injectables Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Allergan, Plc.
  • 10.2 Alma Laser
  • 10.3 Anika Therapeutics, Inc.
  • 10.4 Antares Pharma
  • 10.5 Bausch Health Companies In
  • 10.6 BIOPLUS CO., LTD.
  • 10.7 Bioxis Pharmaceuticals
  • 10.8 Bloomage BioTechnology Corporation Limited
  • 10.9 ColBar LifeScience Ltd.
  • 10.10 Dickinson and Company
  • 10.11 Galderma Pharma S.A.
  • 10.12 Ipsen Pharma
  • 10.13 Medytox, Inc.
  • 10.14 Merz Pharma
  • 10.15 Prollenium Medical Technologies Inc.
  • 10.16 Revance Therapeutics, Inc.
  • 10.17 Sinclair Pharma Plc
  • 10.18 Solta Medical
  • 10.19 Suneva Medical, Inc.
  • 10.20 Syneron Candela
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦